Wo viele Krankheiten giebt giebs auch viel medizin - 500 Beiträge pro Seite

[noor]

Es Handelt sich um eine pharma aktie scheut euch mal denn kurs an in einen land wo viel Krankheiten giebt wird auch ziemlich viel medizin verschrieben weiss ich aus erfahrung dort werden medizin verschrieben als seien es smartis und der pharma sektor in indien ist auch mit der westliceh weld gleich zu sezen was meint ihr dazu

[noor]

Sorry die WKN DER AKTIE LEUTET Dr Reddys LAB 896699 und Sie steigt

[Ronny@pcg]

[Börsenmuschi]

Sobald ich verstanden habe, was Du mit Deinem Pidgin-Deutsch andeuten wolltest, beschäftige ich mich evtl. mal näher mit Deinem Tip.

Legasteniker an die Macht!

[OlliKro]

hi muschi,
kann nur ein ausländischer mitstreiter sein. sei nicht so hart. lässt du nur "Frankfurter" in deine muschi?

[Ronny@pcg]

ich veis nischt fiel fon diese pferdpapier
abber ich verds mier das mal ankukken.

pfrohes wiekend noch

[Börsenmuschi]

Bäääh - pfui!

Man hat mir beigebracht, daß man mit Lebensmitteln nicht spielt.

[noor]

Type: Corporate Issue Related(Public/Rights..)

DR Reddy`s Laboratories (DRL) is at the crossroads. The company has begun to bring together the various arms of its group under one company as it prepares for a radically different environment. As part of its plan to prepare itself for a more competitive era, DRL also plans to tap the equity market in the US soon. In that context, it is interesting to note that media reports suggest that DRL has been discarded from the portfolio of a leading institutional investor. Recent trading patterns suggest that when an institutional trend-setter discards a stock, the counter is gripped by negative sentiment, thereby leading to a lower price. This may also present investors with an opportunity to take an exposure if the company`s fundamentals are sound.

DRL`s share price has slipped about 15 per cent over the last 10 days to trade around Rs 1,233. A few key areas that investors ought to track are given below. Dr Reddy`s started operation as a bulk drug (ingredient for drugs in consumable form) producer in the mid-1980s. The striking feature of the company`s operations since then has been its steady move up from the high-risk bulk drugs business into the more profitable formulations (drugs in consumable form) business. DRL has consistently tried to expand its presence in the formulations business through acquisitions. In November 1999, Dr Reddy`s bought out the stake of the promoters of American Remedies and then initiated steps to bring the company into its fold.

Exporting to the US market is an important part of the strategy of quite a few Indian pharmaceutical companies. DRL`s associate company, Cheminor, has worked towards tapping the US market. Recently, DRL initiated steps to merge Cheminor with itself. The brand and proposed company acquisitions have set the stage where the entire group will soon log a turnover of about Rs 900 crore in a year, thereby making it one of the biggest pharmaceutical firms in the country. This would be a considerable growth over Dr Reddy`s turnover of Rs 250 crore in 1996-97. In this scenario, companies with a huge mass and a presence across many therapeutic segment are more likely to withstand pressure. Dr Reddy`s acquisitions supplement organic growth by allowing the company to straddle quite a few therapeutic segments faster and place it strongly on this front.

The ability to quickly replicate a molecule under patent elsewhere and produce it at a much lower cost is a characteristic that makes the Indian pharmaceutical industry globally competitive. But when the freedom to replicate molecules under patent elsewhere is denied and thereby companies are constrained from introducing new products, most Indian companies may be left holding a relatively static basket of products. DRL has taken the lead in tackling this situation by working on synthesising new chemical entities. So far, DRL has achieved a degree of success in its endeavour. The amount of funds it can set aside for Research & Development (R&D) and its pipeline of products will play a significant role in its future valuation.

[noor]

Type: Corporate Products/Production

HYDERABAD: DRF-2725, an anti-diabetic molecule discovered by Dr. Reddy`s Research Foundation (DRF) and licenced to Novo Nordisk in June 1998, has entered Phase II trials of clinical development. As per the terms of the agreement with Novo Nordisk, this event does not trigger any milestone payments at this point of time, according to a communique from Dr. Reddy`s Labs. DRF-2593 also licensed to Novo Nordisk in March 1997 had entered phase II clinical trials in March 2000, the trials were in progress. DRF drug discovery efforts were sponsored by Dr. Reddy`s Laboratories. So far, the company had received payments of $ 8 millions from Novo Nordisk. In addition to these two licensed compounds, Dr. Reddy`s is actively pursuing five other compounds in the field of cancer, diabetes and pain management. Reddy US Inc., its research outfit based in Atlanta, Georgia, US, was fully operational. This was established to apply molecular, genomic and proteomic approaches for the discovery of new drugs, it added.

[mig48]

@ OlliKro
noor ist kein ausländischer Mitstreiter sondern ein inländisches A....loch.
mig48

[noor]

Thanks mig48
go back too kindergarten

[noor]

Type: Corporate Products/Production

Hyderabad: The anti-diabetic molecule, DRF-2725, discovered by Dr Reddy`s Research Foundation (DRF) and licensed to Novo Nordisk in 1998, has entered phase-II trials of clinical development. However, as per the terms of the agreement with Novo Nordisk, this event does not trigger any mile stone payment at this point.

Another molecule, DRF-2593, also licensed to Novo Nordisk in March 1997, has entered the Phase II trials in March and is in progress. DRF`s drug discovery efforts are sponsored by Dr Reddy`s and so far the company has received milestone payments of $8 million from Novo Nordisk. In addition to these two licensed compounds, the company is actively pursuing five others in the field of cancer, diabetes and pain management.

DRF-1644, a Topoisomerase I Inhibitor anti-cancer compound, is in clinical developent in Europe. NDDO, a well known clinical research organisation specialising in development of anti cancer drugs, has been contracted to conduct the trials. The compound is in late pre-clinical studies. DRF-MDX8, a metabolic disorder drug, has also completed pre-clinical development and is under licensing negotiations. Yet another anti-diabetic compound, DRF-NPCC, which could be developed as an insulin sensitiser, is also ready for initiating licensing negotiations for. Reddy US Inc, established in 1999 and based in Atlanta is now fully operational to aply molecular, genomic and proteomic approaches for the discovery of new drugs, a company release said.

[noor]

Dr. Reddy`s Laboratories Ltd.


Director`s Report

Dr. Reddy`s Laboratories Limited (DRL) has been successfully demonstrating its strength as an Integrated Pharmaceutical Player. The major business highlights of the year under review are :

* Turnover Growth of 28%.

* Finished Dosage business contributed 58% and Bulk Drug business contributed 38% to the total turnover of the Company.

* Product portfolio consolidated by acquisition of brands in Haemostatics/Hepato-protective therapeutic segments.

* Emerging Business achieves a steady and sustained growth of 44% and contributes Rs.141.37 million.

* Research activity results in Dr. Reddy`s Research Foundation (DRF) licensee Novo Nordisk approving DRF 2725, blood glucose and dyslipidemia regulating compound for, clinical development.

* DRF applies for permission to conduct Phase I clinical trial for anti-cancer compound DRF 1042 with the Drugs Controller General of India (DCGI).

* 120 new product registrations in international markets.

* Brazil Joint Venture commences operations and advanced stage of negotiation for a Joint Venture in China.

Finished Dosage Forms

Consolidation of the product portfolio has resulted in a contribution of Rs.2,484.77 million.

Therapeutic Portfolio

The addition of Haemostatic and Hepatostimulant/hepato-protective Segment to the existing segments of Gastroenterology, Cardiovascular, Anti-infective, Pain Control and other Speciality Groups has enhanced DRL`s customer equity.

Indian Finished Dosage Forms Operations

DRL has been ranked 8th in the all India prescription audit by CMARC (Centre for Marketing and Advertising Research Consultancy) and 20th by ORG (Operational Research Group) under the all India retail audit.

* Five brands namely Omez, Nise, Stamlo, Enam and Ciprolet are ranked among the top 250 brands and they have contributed around 64% of the domestic Finished Dosage contribution. Omez, Nise and Stamlo are brand leaders in their respective therapeutic segments.

* The launch of Ciprolet-l00, Reclide-40 (as brand extensions), Ciprolet-A (Ciprofloxacin & Tinidizole combination), Stamace (Amlodipine and Ramipril Combination) Nise Gel (Nimesulide topical Gel) and Denfoss (Aldendranate Sodium) has resulted in consolidating DRL`s market share in these segments.

* Velocit, a pregnancy detection kit developed by Diagnostics division was launched during the year.

* The launch of brands namely Styptovit, Styptochrome, Styptomet, Doxt, Trichodol and Dicynene has enhanced DRL`s customer equity with Gynaecologists, Surgeons, Dentists and Gastroenterologists.

* The launch of Mitotax (Paclitaxel), an anti-cancer compound and Exifine (Terbinafine) an anti-fungal heralded the functioning of the Critical Care division. This division also launched Dacotin (Oxaliplatin), a colorectal cancer drug.

Brand Acquisitions

During the year the Company has acquired the following brands from Dolphin Laboratories Ltd. :

* Styptovit

* Styptochrome

* Styptomet

* Doxt

* Trichodol

The Company has also acquired the marketing rights of Dicynene from OM Pharma, Switzerland.

International Finished Dosage Forms

The Brazilian J. V. (Joint Venture) became operational with the registration of the J. V. under the name of Aurantis Farmaceutica Ltda., and with the effective placement of personnel.

Operations in Sri Lanka, Kenya, and Myanmar have been strengthened with the opening of liaison offices. A business manager has been appointed for Yemen and the plans to enter Middle East are being worked out.

DRL also launched its brands in Venezuela and in the process became the first Indian Company to market its products in that country.

DRL is also finalising its plans to enter the US $ 12 billion Chinese market through setting-up of a J. V. there to overcome import restrictions in that country.

This J. V. would also result in DRL realising a better value addition for its products.

Russian Rouble devaluation and the unstable currency situation resulted in suspension of trade with Russia and other Central Asian Republics for a brief period of time. The business has now been restored after the improvement of the economic situation. Overall export growth in this market had been negative during the year under review because of the cautious decision taken keeping in view of the devaluation of the Rouble and volatility of the situation in Central Asian Republics.

Bulk Actives Business

The Bulk Active segment of the pharmaceutical industry is passing through a phase of consolidation as almost 80% of the domestic market share of many high volume drugs are concentrated in the hands of two or three players. This segment also witnessed marketing tie-ups between major Bulk and Finished Dosage companies. This sector continues to operate in a very competitive environment. Against this backdrop, the Bulk Actives business of DRL achieved a sales turnover of Rs. 1632.43 million, against Rs. 1155.75 million during the previous financia year.

Indian Bulk Actives Business

Recorded a sales turnover of Rs. 1051.21 million, registering a growth of 58% over the sales of Rs.664.72 million during the same period last year. This could be achieved by laying increased emphasis on anti- ulcerants segment.

DRL also bagged the Best Vendor Award given by the OPPI (Organisation of Pharmaceutical Producers of India) for the year 1997-98. This award is given on the basis of a complex rating system adopted by its 300 members for the Bulk Drug supplier`s product quality, timely delivery, price stability and responsiveness.

International Bulk Actives business also operated in a highly competitive environment. Notwithstanding the competition, the international operation contributed Rs.581.23 million, representing a growth of 18% over the last year and is also expected to enter the generics markets after its facilities obtain the USFDA (United States Federal Drug Authority) approval.

Emerging Businesses

The Diagnostics business of the Company continues to make steady progress by recording a sales turnover of Rs.141.37 million as compared to Rs.97.91 million during the previous year in the process achieving a growth of 44%. This division successfully developed the pregnancy kit, Velocit and has supplied the same to the Finished Dosages division for marketing through their existing sales network.

The Diagnostics division has obtained an ISO 9002 certification issued by DNV (Det Norske Veritas) under the accreditation scheme of ENAC, Spain. It has become the first diagnostics facility in India to receive DNV certification that covers marketing, distribution and customer relations apart from production, quality control, R&D, purchase, and training and development.

Critical Care division had successfully launched Oxaliplatin under the brand name Dacotin, an anti-cancer drug used for treatment of cob-rectal cancer. Mitotax, another anti-cancer drug used for treatment of breast and ovarian cancer has surpassed all the targets for the current year and is expected to contribute substantially in the coming year. This division has lined up some of the major product launches for the coming year as well.

Bio-technology division has developed a strong technology platform for recombinant protein production. The Company expects to launch two products in the coming year.

Research & Development

DRL continues to sponsor Drug Discovery work at Dr. Reddy`s Research Foundation, which will help the Company to compete in a post-GATT environment when the product patent regime comes into effect in India. Apart from cancer and diabetics, DRF is also focussing on research in ulcer, bacterial infection and inflammation. The emphasis by DRL on basic research has resulted in the discovery of a second anti-diabetic molecule DRF 2725, a blood glucose dyslipidemia-regulating compound, which has been approved by the Licensee Novo Nordisk for clinical development. The first molecule DRF 2593 is in the Phase 1 trials and is expected to move on to Phase II. Company had invested Rs.93.95 million during the year towards research and development which represents 2.20% of the turnover.

Financial Performance

The Company, during the year, had made a sizeable investment in acquiring brands and significant effort in setting up Joint Ventures in new markets which will start yielding results in the coming years. The overall sales grew by 28% over the last year, operating profit grew by 16.75%.

Rs. Million

1998-99 1997-98

Income 4,315.36 3,351.86

Gross Profit 699.17 598.90

Depreciation 101.56 65.45

Profit before Tax 597.61 533.45

Taxation 80.00 45.00

Net Profit for the year 517.61 488.45

Add : Profit and Loss brought forward 3.41 2.37

Total available for appropriation 521.02 490.82

Appropriations :

General Reserve 430.00 400.00

Provision for Current Year`s Dividend 79.46 79.46

Reserve for Corporate Dividend Tax 7.95 7.95

Profit & Loss Account balance carried forward 3.61 3.41


Directors recommend a dividend of Rs.3/- per share for the year under review.

* Detailed financial statement along with notes and accounting policy annexed.

Human Resources Development

The highlight of HR (Human Resources) initiatives this year was bringing in sharper focus on performance orientation through operational excellence and cross-functional goals. Training & Development initiatives focussed on enhancement of team specific skills for achieving immediate business objectives like USFDA approval. Programmes held included upgrading communication skills in English Language, Manufacturing Excellence, Selling & Negotiation Skills and Team Building through Out-bound programmes. Another major drive was on health management and awareness through structured Executive Lifestyle Management programmes.

The focus this year will be on simplifying and integrating the HR systems to make them more transparent and employee friendly for high motivation. A major thrust will be on competency profiling and development for building global teams.

Year 2000 (Y2K) Compliance

DRL uses SAP R3, ERE (Enterprise Resource Planning) software which is Y2K compliant and functions as an integrated business application system. DRL had given top priority to Y2K compliance and had moved to translate plans into specific actions and to remedy and replace hardware, operating systems and other software applications and equipment if necessary. The Y2K problem was addressed at all levels and the project had commenced from May 1998 and will be completed by June 1999. For this DRL had hired the services of a leading Y2K solution provider. DRL intends to validate all components periodically and take remedial measures in case of any deviations.

DRL does not foresee any Y2K related issue affecting its operations. DRL has allocated Rs.28.69 million and has already incurred Rs. 16.15 million to address the Y2K issue. DRL also intends to take an insurance policy for overcoming any loss resulting from the possible failure of its vendors operation due to the Y2K problem.

Subsidiary Company

Reddy Pharmaceuticals Hong Kong Ltd

Reddy Pharmaceuticals Hong Kong Ltd., registered a sales growth of over 100% during the year. Sales increased from US$ 3.63 million to USS 8.10 million. The growth in the sales turnover has been due to the increased focus in trading activities of Bulk Actives and Finished Dosages. The Company achieved a net profit of US$ 301,784. The Company declared a dividend of US$ 100,000 for the year.

Reddy Pharmaceuticals Singapore PTE Ltd

Reddy Pharmaceuticals Singapore Pte Ltd. recorded turnover of US$ 2.06 million. The restructuring operations undertaken during last year has resulted in the subsidiary posting a profit of US$ 52,733 during the year.

Reddy Biomed Ltd

Reddy Biomed had an eventful year with the crash of the Russian Rouble and fluid economic conditions of the Central Asian Markets. In this backdrop the Company achieved a sales turnover of US$ 9.98 million. The crisis had an effect on the operations of the Company only for a brief period of time. Monthly realisations during the second half of the financial year were above US$ 1.00 million. Net profit for the year was US$ 1.62 million.

Reddy Netherlands B. V.

Reddy Netherlands B.V., is a wholly owned subsidiary. The Company recorded a net profit of US$ 85,633 on a total income of US$ 2.06 million.

Reddy Antilles N. V.

Reddy Antilles N. V. has recorded an income of US$ 1.74 million and a net profit of US$ 1.27 million. The Company proposes a dividend of US$ 100,000 for the year.

Compact Electric Ltd

The Company`s effort to export the products started bearing results, with the receipt of trial orders from some of the leading world class companies. The quality of the products have been well accepted by these companies and repeat orders have also been placed. The Company expects to meet its target in the coming years.

Corporate Citizen

The Company is aware of its responsibility as a corporate citizen and has initiated many social and welfare activities through Dr. Reddy`s Foundation for Human and Social Development (DRFHSD). DRFHSD embodies the social conscience of DRL. The Foundation has developed the programme at four levels :

* Developing new sustainable models.

* Enabling its own models to reach scale.

* Supporting models of other agencies and helping these to achieve scale.

* Support programme developed in collaboration with other business groups.

Some of the programmes under various levels are :

* MES (Micro-entrepreneurs in Sanitation).

* CAP (Child and Police Programme).

* Change Makers` Club.

* Micro credit through Share Organisation.

* Tailoring training for women through guild of service.

* Bloodline.

* Automobile Mechanic Training.

Commitment to Environment

DRL in its pursuit of providing a clean and healthy environment has commissioned its second effluent treatment plant at its manufacturing facility and thus attaining a unique status of zero discharge from its manufacturing facility. The Company also has continuously developed and re-engineered its manufacturing process in order to device a new and innovative process of manufacturing, which resulted in lesser effluent generation.

Safety

The Company has been able to maintain a zero accident record at its manufacturing facility.

Directors

Mr. G. V. Prasad, Mr. Kamlesh S. Gandhi, and Mr. A. Subba Reddy, Directors of the Company retire by rotation at the forthcoming Annual General Meeting and being eligible, offers themselves for reappointment.

Auditors

M/s. A. Ramachandra Rao & Co., Chartered Accountants, the statutory auditors of the Company retire at the ensuing Annual General Meeting and are eligible for re-appointment.

Cost Audit

Under Section 233 B of the Companies Act, 1956, Cost Audit of the Company`s Bulk Actives division and Finished Dosages division has been prescribed by the Government of India. The cost audit is under process and the Company will submit the cost auditors report to the Government in time.

Disclosure of Particulars

As required by the Company (Disclosure of Particulars in the Report of Board of Directors) Rules, 1988, the relevant information and data are given in Annexure to this report.

Particulars of Employees

Under the Provisions of Section 217(2A) of the Companies Act, 1956 read with Companies (Particulars of Employees) Rules, 1975 as amended, the names and other particulars of employees are set out in the annexure to the Directors` Report. However, in terms of the provisions of Section 219 (1)(b)(iv) of the Companies Act, 1956, the Directors` Report is being sent to all the share holders of the Company excluding the aforesaid annexure. Any shareholder interested in obtaining a copy of the said annexure may write to the Company Secretary at the Registered Office of the Company.

Dr. Reddy`s had 2310 employees as of 31st March, 1999 of whom six employees who were employed through out the year were in receipt of remuneration exceeding Rs.600,000/- per annum and two employees who were employed for part of the year who were in receipt of Rs.50,000/- per month.

Particulars Regarding Energy Conservation, etc. Information regarding Energy Conservation and Technology Adoption required to be disclosed under Section 217(2A) of the Companies Act, 1956 read with the Companies (Disclosure of particulars in the report of Board of Directors) Rule, 1988 is annexed hereto and the same forms part of this report.

FORM - B

Form for disclosure of particulars with respect to absorption

Research and Development (R&D)

1. Specify areas in which R&D is carried out by the Company :

I) Development of lab scale process for pharmaceutical products with a good market potential worldwide.

II) Development of alternate routes of synthesis for products already commercialised. Study of impurity profile of products.

III) Pharmaceutical products for human care, analytical method development, clinicall pharmacokinetic studies, quality improvement, packaging development.

2. Benefits derived as a result of the above R&D :

1) Commercial production of the following products has commenced.

* Losartan Potassium

* Ramipril

* Alendronate Sodium

* Esmolol Hydrochloride

II) (1) Developed and introduced products in therapeutic areas of : (a) Anti-inflammatory (Diclostan 50, Naprogen) (b) Anti-bacterials (Ciprolet A, Ciprolet AH) (c) Anti-hypertensives (Stamace) (d) Anti-viral (Klovir 200, Klovir 400) (e) Anti-cancer (Mitotax, Mitotax 100) (f) Osteoporosis (Denfos). (2) Developed first sustained release product of the Company for Anti-hypertension (Imnit 30, Imnit 60). (3) Developed and introduced Ciprolet 100, Reclide 40, Nise kid, Nise gel and Zolstan tablets as line extensions for existing products. (4) Analytical methods developed for the following therapeutic segments : (a) Anti-hypertensives (b) Anti-diabetics (c) Anti-inflammatories (d) Anti-histamines (e) Anti-cancer (f) Anti-ulcer products. (5) Clinical trials and bio-equivalent studies completed for identified molecules. (6) Cost improvement by replacing some of the imported materials with indigenous materials and reduction in process time.

3. Future plan of action :

(1) Commercialisation of products at present undergoing trials at pilot plant level. (2) Development of new products in the therapeutic segments of Gastro-intestinal disorders, Anti-inflammatory, Anti-diabetics, Anti-cancer, Anti-hypertensives, Anti-cholesterolaemia, Anti-oxidant, Anti-asthma, Anti-bacterials. (3) Development of analytical methods for the new products. (4) Development of new products for Critical Care division. (5) Development of Finished Dosage forms for International marketing. (6) Development of innovative packaging materials. (7) Improvements in quality and productivity. (8) Clinical trials and bio-equivalence studies for new drugs. (9) Develop process that ensures total treatment of effluents generated.

4. Expenditure on R&D : In Rupees

1998-99 1997-98

a) Capital 59,871,192 41,502,150

b) Recurring 34,079,186 29,246,834

c) TOTAL 93,950,378 70,748,983

d) Total R&D expenditure as a 2.20% 2.12% percentage of total turnover

Technology absorption, adaptation and innovation

1) Efforts, in brief, made towards technology absorption, adaptation and innovation :

The Company has a full-fledged R&D Division continuously engaged in research on new products and development of existing products. The Company has developed indigenous technology in respect of the products manufactured by them. The Company has filed six process patents in India and one patent abroad.

2) Benefits derived as a result of the above efforts, e.g. product improvement, cost reduction product development, import substitution, etc. :

Product quality improvement, cost reduction, product development and import substitution. The continuous improvement and adoption of technology has benefited the Company in the form of better production process, better yields, cost reduction and quality of the end products.

3) In case of imported technology (imported during the last 5 years reckoned from the beginning of the financial year) following information may be furnished :

No imported technology, product quality improvement, cost reduction, product development and import substitution. The continuous improvement and adoption of technology has benefited the Company in the form of better production process, better yields, cost reduction and quality of the end products.

a) Technology imported

b) Year of import

c) Has technology been filly absorbed?

d) If not fully absorbed, areas where this has not taken place, reason thereof and future plan of action

FORM - C

The information on foreign exchange earning and outgo is given in item no. 10 (d) 1, 2, 3 & 4 in Notes On Accounts.

[noor]

Dr. Reddy`s Laboratories Ltd.


Company History
YEAR EVENTS 1985 - The Company was Incorporated on 2nd November. The Company was promoted by Dr. K. Anji Reddy and his associates who were also the promoters of Standard Organics, Ltd.

- In May, the Company issued 7,50,000 equity shares of Rs 10 each for cash at par linked to 1,50,000 - 15% secured redeemable non-convertible debentures of Rs 100 each for cash at par in the proportion of one debenture for five equity shares held including the oversubscription from the public. The allotment was made as follows:

- (i) 12,550 equity shares linked to 2,510 debentures were issued to business associates

- (ii) 850 shares linked to 170 debentures were issued to the employees

- (iii) 2,80,500 shares linked to 56,100 debentures issued to the non-resident Indians and (iv) 5,25,850 shares linked to 1,05,170 debentures were issued to the public.

1986 - 10,06,500 equity shares then issued at par out of which 2,56,500 equity shares were reserved and allotted to promoters, etc. The remaining 7,50,000 equity shares were issued linked to debentures of which the following shares were reserved for preferential allotment:

- (i) 15,000 shares to business associates of the Company (only 12,550 shares taken up);

- (ii) 37,500 shares to employees of the company (only 850 shares taken up) and 3,00,000 shares to non-resident Indians (only 2,80,500 shares taken up). The balance 3,97,500 shares along with the unsubscribed portion of 58,600 shares out of the preferential quota were offered for public subscription during June.

- 1,16,250 additional shares linked to debentures were allotted to retain oversubscription (46,500 shares to promoters and 69,750 shares to the public.

1988 - 13,660,500 No of equity shares forfeited.

- (15 months), a plan was drawn for the expansion and modernisation of formulations division. ICICI and IFCI sanctioned term loans of Rs 198 lakhs and Rs 132 lakhs respectively.

1989 - An explosion at the Company`s plant resulted in stoppage of production for 2 months. Two new products namely, a Ciprolet and Enam were introduced by the Company`s formulation division while the Company`s bulk drug division commenced manufacture of ciprofloxacin, a new drug. The Company exported goods such as Methyldopa, Cephalexin etc., worth Rs 2.68 crores.

- 6,83,125 rights shares issued (prem. Rs. 15 per share; prop. 1:2). Additional 1,02,470 shares allotted to retain oversubscription. Another 34,155 shares (prem. Rs 15 per share) allotted to employees. 1990 - The Company started manufacturing a new bulk drug by the name Omeprazole which was launched in the market by the brand name `OMEZ`.

1991 - 10,92,950 bonus equity shares issued in prop. 1:2.

1992 - 32,78,850 bonus equity shares issued in prop. 1:1.

1993 - Subject to necessary approvals being obtained, a separate company in the name of `Dr. Reddy`s Dignostics Ltd.` was to be set up for the manufacture of dragnostics kits. The Company proposes to invert to the extent of 60% in the equity capital of the company.

1994 - The Company proposed to invest Compact Electric Ltd., which was in the process of setting up a plant at Chennai for manufacturing energy efficient electric filament/discharge lamps in Collaboration with Li-Tech Corporation, South Korea. The Company set up a subsidiary `Reddy Hong Kong Ltd.` in Hong Kong for marketing the Company`s products in Main Land China and Far East countries.

- `Reddy Biomed Ltd.` was incorporated as a joint venture between the Company and a Russian Company `Joint Stock Company of open type named after 1:1. Machnikov` for manufacturing and marketing formulation in Russia.

- Effective 1st April, Standard Equity Fund was merged with the Company. Pursuant to the scheme of amalgamation 2,63,062 equity shares of Rs 10 each of the Company were issued to the shareholders of erstwhile Standard Equity Fund in the ratio of one equity share of the Company for ten equity shares of the erstwhile Standard Equity Fund Ltd.

- During July the Company issued 4301076 Global Depository Receipts at a price of US $11.16 per GDR. The Company allotted 4301076 equity shares of Rs 10 each at a premium of Rs 340 per share underlying the GDRs.

1995 - Formulation division launched two new products namely Lanzap, an anti-Ulcerant drug and Peristil, drug for gastric disorder. The bulk drug division commenced the production of six new products viz., Finasteride, Nimesulide, Fluoxetine, Hydrochloride, Terbinafine, Hydrochloride, Risperidone and Clozapine. The Company was in the process of setting up a subsidiary in the Antilles Kingdom of Netherlands for licensing the manufacture and marketing of drugs.

- 263,062 equity shares issued to the shareholders of erstwhile standard Equity Fund Ltd. Pursuant to the scheme of amalgamation.

1996 - Four new products viz. Nise, Stamlo Beta, Sparfloxacin and Finast were launched. Finast, a drug for treatment of benign prostiate enlargement was launched for the first time in India. Under the bulk drugs category two new drugs viz. Sparfloxacin & Croratidine were launched.

- The diagnostics division entered into a technical collaboration agreement with Board of Radiation and Isolope, technology for manufacture & marketing of radioimmonuassay kits for the production of diagnostic and therapeutic recombinant protections, the Bio-technology division entered into a technical collaboration agreement with Viral Therapeutics Inc. U.S.A.

1997 - In view of the company`s long term plans in the area of diabetic care, the company launched Reclide (Glicazide), its first product in the theraupeutic segment. Also, in its commitment to promote innovative products, the company entered into a marketing alliance to market Netacryl, a bio adhesive (n-butyl-2-cyno acrylate) used for the closure of external surgical and post traumatic wounds.

- The Company set up a Critical care division to commercialise products from the research foundation and the first product to be marketed by the division was Miitotax an anti-cancer product used in the treatment of breast and ovarian cancer.

- The city-based drug major Dr. Reddy`s Laboratories has perfected the formulation of an anti-diabetic compound, glitazone for commercial marketing.

- DRF has signed a licensing agreement with the Denmark-based Novo Nordisk, according to which the latter would obtain an exclusive worldwide license to develop and market pharmaceutical products based on compounds discovered and patented by the former.

- Dr. Reddy`s Research Foundation has finally signed the agreement for clinical testing of its four diabetes compounds of glitazone with the European drug major; Nova Nordisk.

- Dr Reddy`s Labs, the Hyderabad based pharmaceutical company, is forming two new joint ventures in Brazil and Uzbekistan.

- The Hyderabad-based Dr Reddy`s Laboratories is manufacturing an anti-ulcer formulation right from the basic stage for competitor, Ranbaxy Laboratories, as part of its strategy aimed at creating more value for its bulk drugs.

1998 - Dr. Reddy`s Laboratories (DRL) has launched its first anti-cancer drug Mitotax (Paclitaxel). The product is produced in-house at Dr. Reddy`s Research Foundation (DRF) from the extracts of the yew tree and formulated in a dedicated facility in Hyderabad.

- Dr. Reddy`s Laboratories (DRL) has ended its collaboration with the French company, bioMerieux. The collaboration agreement, which envisaged DRL to market bioMerieux`s diagnostic reagents and instruments in India, has come to an end on 13th November.

- Dr. Parvinder Singh, Chairman & Managing Director of Ranbaxy Laboratories and Dr. K Anji Reddy, Chairman of the Rs 5000 million Dr. Reddy`s Group of pharmaceutical companies, were conferred with the prestigious `Ishidate Award` of the Federation of Asian Pharmaceutical Associations (FAPA).

1999 - Dr. Reddy`s Laboratories Ltd. (DRL) has set up an in-house effluent treatment plant at its bulk pharmaceuticals manufacturing facility located at Bollaram Industrial Development Area.

- Dr. Reddy`s Laboratories is setting a new trend in the Indian pharmaceutical sector by installing a `satellite` discovery research laboratory in the United States.

2000 - Dr. Reddy`s Laboratories and the Gribbles Group of Australia have signed a memorandum of understanding to form a joint venture company for establishing a network of 50 pathology laboratories and up to 200 specimen collection centres in India over the next five years.

- The Board has approved merger of Cheminor Drugs Ltd. with the company. Nine equity shares of the company will be allotted for every 25 equity shares of CDL held. The Company has decided to issue 7,50,000 equity shares under ESOS.

- The employees of the formulation unit-II of the company at Bachupally have decided to go on an indefinite strike from 17th June.

- The Company has introduced a five-day week from January and change in timings. A small group of employees has called for a strike from June 19.

- For the first time in the country, pharma major Dr. Reddy`s Laboratories has launched an initiative to document clinical studies of drugs on the Internet.

- DRF 2725, an anti-duabetic molecule discovered by Dr. Reddy`s Research Foundation and licensed to Novo Nordisk in June 1998, has entered phase II trials of clinial development.

- Dr. Reddy`s Laboratories Ltd., the Hyderabad-based pharmaceutical company, has acquired three brands in the segment of women`s health from Dai-Ichi Karkaria Ltd.

[mig48]

@ noor
Du bist eine miese Ratte. Es ist traurig, dass man gegen solche Schweine wie Dich
nichts unternehmen kann.
Ich wünsche Dir alles schlechte!
Mögen Zehntausend Kamel-Flöhe Dein Arschloch heimsuchen!

Hier einige Beweise:
Thread: Rüstungs industrie
Thread: TATA akten(india)
Thread: Wer von euch hat im business Keine Moral

mig48

[Ronny@pcg]

@ mig48

you are welcome



@ noor



@ all

[Nix Wasa]

Hi All !!!

Zu Noor es schreibt zwar wenig,weiss aber immer noch nicht warum gerade er auf die Aktie gekommen ist.

Die Aktie bzw das Unternehmen ist eines der Aussichtsreichsten Unternemen in Inden.

Ist aber gegen Shante Biotechnics und Bahrat Biotech ein wasers in der Indischen Biotech Brance.
Für die was nicht im Bilde sind was los ist


Nr 19 Emergin Markets Biotechwerte : Dr.Reddys Laboratories


Mkp: 1,5 Mld.

Umsatz: die letzen 4 Quartale:ca. 155Mil $.

Total Income 03.2001 2.637 Mil rs. +18 %
Total Income: 12.2000: 2,228 Mil rs. +33%
Total Income: 09.2000: 1,669 Mil rs +19 %
Total Income: 06.2000: 1,401 Mil rs. +8 %
Total Income: 03.2000: 1,293 Mil rs. +7 %
Total Income: 12.1999: 1,213 Mil rs. + 6 %
Total Income: 09.2000 : 1,145 Mil rs. –10 %
Total Income: 06.1999 : 1,265 Mil rs


Nix Wasa